Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biochim Biophys Acta Biomembr ; 1860(3): 691-699, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29253504

ABSTRACT

The effects of dipole modifiers, thyroid hormones (thyroxine and triiodothyronine) and xanthene dyes (Rose Bengal, phloxineB, erythrosin, eosinY and fluorescein) on the pore-forming activity of the lipopeptide syringomycin E (SRE) produced by Pseudomonas syringae were studied in a model bilayer. Thyroxine does not noticeably influence the steady-state number of open SRE channels (Nop), whereas triiodothyronine decreases it 10-fold at -50mV. Rose Bengal, phloxine B and erythrosin significantly increase Nop by 350, 100 and 70 times, respectively. Eosin Y and fluorescein do not practically affect the pore-forming activity of SRE. Recently, we showed that hormones decrease the dipole potential of lipid bilayers by approximately 60mV at 50µM, while Rose Bengal, phloxine B and erythrosin at 2.5µM reduce the membrane dipole potential by 120, 80 and 50mV, respectively. In the present study using differential scanning microcalorimetry, confocal fluorescence microscopy, the calcein release technique and measurements of membrane curvature elasticity, we show that triiodothyronine strongly affects the fluidity of model membranes: its addition leads to a significant decrease in the temperature and cooperativity of the main phase transition of DPPC, calcein leakage from DOPC vesicles, fluidization of solid domains in DOPC/DPPC liposomes, and promotion of lipid curvature stress. Thyroxine exerts a weaker effect. Xanthene dyes do not influence the phase transition of DPPC. Despite the decrease in the dipole potential, thyroid hormones modulate SRE channels predominantly via the elastic properties of the membrane, whereas the xanthene dyes Rose Bengal, phloxine B and erythrosine affect SRE channels via bilayer electrostatics.


Subject(s)
Depsipeptides/drug effects , Fluorescent Dyes/pharmacology , Lipopeptides/drug effects , Membrane Fluidity/drug effects , Peptides, Cyclic/drug effects , Thyroxine/pharmacology , Triiodothyronine/pharmacology , Xanthenes/pharmacology , Calorimetry, Differential Scanning , Depsipeptides/pharmacology , Elasticity , Electric Conductivity , Fluoresceins/metabolism , Lipid Bilayers , Lipopeptides/pharmacology , Liposomes , Membrane Lipids/chemistry , Microscopy, Confocal , Microscopy, Fluorescence , Nanotubes , Peptides, Cyclic/pharmacology , Phospholipids/chemistry
2.
Respir Physiol Neurobiol ; 187(2): 157-63, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23537586

ABSTRACT

Inhaled nitric oxide (NO) causes selective pulmonary vasodilatation and may improve gas exchange. The study was aimed to evaluate the acute effects of inhaled NO on pulmonary gas exchange in severe unilateral pneumonia, where hypoxemia results from increased intrapulmonary shunt. We studied 8 patients without preexisting lung disease (59±18 yr; 4M/4F) with early unilateral severe pneumonia and respiratory failure. Pulmonary and systemic hemodynamics and gas exchange, including ventilation-perfusion (V;A/Q;) distributions, were measured at baseline and while breathing 5 and 40 parts per million (ppm) of NO. Inhaled NO caused a dose-dependent fall in pulmonary vascular resistance (by 12% and 21%, with 5 and 40ppm, respectively; p<0.01, each) and improvement of PaO2 (by 25% and 23%; p<0.05, each), owing to the reduction of intrapulmonary shunt (by 23% and 27%; p<0.05, each), without changes in the amount of perfusion to low V;A/Q; ratio alveolar units. Patients with greater baseline intrapulmonary shunt exhibited greater improvement in arterial oxygenation (r(2)=0.55, p<0.05). We conclude that low doses of inhaled NO improve pulmonary gas exchange in acute severe pneumonia.


Subject(s)
Bronchodilator Agents/administration & dosage , Nitric Oxide/administration & dosage , Pneumonia/therapy , Administration, Inhalation , Aged , Analysis of Variance , Blood Pressure/drug effects , Depsipeptides/drug effects , Female , Functional Laterality , Hemodynamics/drug effects , Humans , Hyperemia/complications , Hyperemia/therapy , Male , Middle Aged , Pneumonia/complications , Pneumonia/microbiology , Pulmonary Gas Exchange , Young Adult
3.
J Neurosci ; 27(40): 10912-7, 2007 Oct 03.
Article in English | MEDLINE | ID: mdl-17913925

ABSTRACT

Rett syndrome (RTT) is caused by loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2). Although MeCP2 is thought to act as a transcriptional repressor of brain-derived neurotrophic factor (BDNF), Mecp2 null mice, which develop an RTT-like phenotype, exhibit progressive deficits in BDNF expression. These deficits are particularly significant in the brainstem and nodose cranial sensory ganglia (NGs), structures critical for cardiorespiratory homeostasis, and may be linked to the severe respiratory abnormalities characteristic of RTT. Therefore, the present study used Mecp2 null mice to further define the role of MeCP2 in regulation of BDNF expression and neural function, focusing on NG neurons and respiratory control. We find that mutant neurons express significantly lower levels of BDNF than wild-type cells in vitro, as in vivo, under both depolarizing and nondepolarizing conditions. However, BDNF levels in mutant NG cells can be increased by chronic depolarization in vitro or by treatment of Mecp2 null mice with CX546, an ampakine drug that facilitates activation of glutamatergic AMPA receptors. Ampakine-treated Mecp2 null mice also exhibit marked functional improvement, characterized by restoration of normal breathing frequency and minute volume. These data demonstrate that BDNF expression remains plastic in Mecp2 null mice and raise the possibility that ampakine compounds could be of therapeutic value in the treatment of RTT.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Depsipeptides/drug effects , Dioxoles/therapeutic use , Gene Expression Regulation/drug effects , Piperidines/therapeutic use , Rett Syndrome/drug therapy , Rett Syndrome/physiopathology , Analysis of Variance , Anesthetics, Local/pharmacology , Animals , Animals, Newborn , Brain-Derived Neurotrophic Factor/genetics , Cells, Cultured , Disease Models, Animal , Gene Expression Regulation/genetics , Methyl-CpG-Binding Protein 2/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Neurons/drug effects , Neurons/metabolism , Nodose Ganglion/cytology , Plethysmography/methods , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction/methods , Tetrodotoxin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...